Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Conferences/ASCO Multiple Myeloma News Source Type: news